Shares of Hyperion Therapeutics soared nearly 20% today after receiving notice that the Food and Drug Administration would not meets its January PDUFA date for Ravicti. However, the reasons for the UCD drug's delay have the bulls out in full force. Watch as Motley Fool health care analyst David Williamson explains what has investors so excited and what it means for Hyperion.
